A global pharma company with a $4.2B franchise approaching loss of exclusivity used CI Scenario Simulations to war-game three biosimilar entry scenarios — from orderly single-entrant to full price war. The exercise surfaced a pricing corridor vulnerability that changed authorized generic timing by four months and identified an optimal contracting window six months earlier than the franchise team had planned. Five interconnected decisions — AG timing, price corridor, contracting strategy, patient transition, and franchise sequencing — were stress-tested against realistic competitive scenarios simultaneously.